文献速递瓣膜病与结构性心脏病冠心病

ShortCut瓣叶改良术在TAVI高危冠脉阻塞患者中的研究

Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study.
PubMed 文献 · Eur Heart J · 2024-01-01

主要安全终点为出院或7天内手术相关死亡或卒中,主要疗效终点为每患者瓣叶切割成功率。结果显示瓣叶切割成功率达100%,主要安全终点无事件率为98.3%,无死亡,1例致残性卒中;30天免于冠脉阻塞率为95%,90天免于死亡率为95%且无心血管死亡。结论认为ShortCut瓣叶改良术安全有效,临床结局良好。

要点

  • ShortCut装置在TAVI术前进行瓣叶改良,瓣叶切割成功率达100%。
  • 主要安全终点(出院或7天内死亡或卒中)无事件率为98.3%,无死亡,1例致残性卒中。
  • 30天免于冠脉阻塞率为95%,90天免于死亡率为95%且无心血管死亡。

核心结论

  • 使用ShortCut对衰败生物瓣膜进行瓣叶改良是安全的,所有患者均实现成功瓣叶切割,并在TAVI高危冠脉阻塞患者中伴随良好临床结局。

研究设计与样本

  • 主要安全终点为出院或7天内手术相关死亡或卒中,主要疗效终点为每患者瓣叶切割成功率。
  • 独立血管造影、超声心动图和计算机断层扫描核心实验室评估所有图像,安全事件由临床事件委员会和数据安全监测委员会裁定。

主要发现

  • 患者平均年龄77.0 ± 9.6岁,70%为女性,96.7%为衰败的外科生物瓣膜,63.3%行单瓣叶切割,36.7%行双瓣叶切割。
  • 瓣叶切割成功率为100%(95%CI 94%-100.0%,P < .001)。
  • 包括影像确认瓣叶切割的手术时间为30.6 ± 17.9分钟。
  • 主要安全终点无事件率为98.3%(95%CI 91.1%-100%),无死亡,1例(1.7%)致残性卒中。
  • 30天免于冠脉阻塞率为95%(95%CI 86.1%-99.0%),90天免于死亡率为95%(95%CI 86.1%-99.0%),无心血管死亡。

临床怎么用

  • 对于因生物瓣膜衰败拟行TAVI且存在冠脉阻塞风险的患者,可考虑在TAVI术前使用ShortCut装置进行瓣叶改良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This trial sought to assess the safety and efficacy of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients at risk for coronary artery obstruction. METHODS: This pivotal prospective study enrolled patients with failed bioprosthetic aortic valves scheduled to undergo TAVI and were at risk for coronary artery obstruction. The primary safety endpoint was procedure-related mortality or stroke at discharge or 7 days, and the primary efficacy endpoint was per-patient leaflet splitting success. Independent angiographic, echocardiographic, and computed tomography core laboratories assessed all images. Safety events were adjudicated by a clinical events committee and data safety monitoring board. RESULTS: Sixty eligible patients were treated (77.0 ± 9.6 years, 70% female, 96.7% failed surgical bioprosthetic valves, 63.3% single splitting and 36.7% dual splitting) at 22 clinical sites. Successful leaflet splitting was achieved in all [100%; 95% confidence interval (CI) 94%-100.0%, P < .001] patients. Procedure time, including imaging confirmation of leaflet splitting, was 30.6 ± 17.9 min. Freedom from the primary safety endpoint was achieved in 59 [98.3%; 95% CI (91.1%-100%)] patients, with no mortality and one (1.7%) disabling stroke. At 30 days, freedom from coronary obstruction was 95% (95% CI 86.1%-99.0%). Within 90 days, freedom from mortality was 95% [95% CI (86.1%-99.0%)], without any cardiovascular deaths. CONCLUSIONS: Modification of failed bioprosthetic aortic valve leaflets using ShortCut was safe, achieved successful leaflet splitting in all patients, and was associated with favourable clinical outcomes in patients at risk for coronary obstruction undergoing TAVI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Dvir D, Tchétché D, Leon MB, et al. Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study. Eur Heart J. 2024. PMID: 38747561. doi:10.1093/eurheartj/ehae303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。